Silence Therapeutics Plc Expected to Earn FY2022 Earnings of ($0.44) Per Share (NASDAQ:SLN)
Silence Therapeutics Plc Expected to Earn FY2022 Earnings of ($0.44) Per Share (NASDAQ:SLN)
Silence Therapeutics plc (NASDAQ:SLN – Get Rating) – HC Wainwright issued their FY2022 earnings estimates for shares of Silence Therapeutics in a research report issued to clients and investors on Tuesday, December 6th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.44) per share for the year. HC Wainwright has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Silence Therapeutics' current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Silence Therapeutics' Q4 2022 earnings at $0.45 EPS, Q1 2023 earnings at ($0.47) EPS, Q2 2023 earnings at ($0.42) EPS, Q3 2023 earnings at ($0.43) EPS, Q4 2023 earnings at $0.06 EPS, FY2023 earnings at ($1.38) EPS, FY2024 earnings at ($1.63) EPS, FY2025 earnings at ($1.71) EPS and FY2026 earnings at ($1.78) EPS.
沉默治疗公司(纳斯达克代码：SLN-GET评级)-HC Wainwright在12月6日星期二发布给客户和投资者的一份研究报告中发布了他们对沉默治疗公司股票2022财年收益的预期。HC Wainwright分析师P.Trucchio预计，该公司今年的每股收益将达到0.44美元。HC Wainwright对该股的评级为买入，目标价为80.00美元。对Silence Treeutics目前全年收益的普遍估计为每股1.10美元。HC Wainwright还发布了对Silence Treateutics 2022年第四季度每股收益的预测，2023年第一季度每股收益(0.47美元)，2023年第二季度每股收益(0.42美元)，2023年第三季度每股收益(0.43美元)，2023年第四季度每股收益0.06美元，2023财年每股收益(1.38美元)，2024财年每股收益(1.63美元)，2025财年每股收益(1.71美元)和2026财年每股收益(1.78美元)。
Separately, Chardan Capital reduced their price target on shares of Silence Therapeutics from $33.00 to $29.00 and set a "buy" rating on the stock in a research report on Thursday, November 17th.
另外，查丹资本在11月17日(星期四)的一份研究报告中将Silence Treateutics的股票目标价从33.00美元下调至29.00美元，并对该股设定了“买入”评级。
Silence Therapeutics Trading Down 3.7 %
沉默治疗公司股价下跌3.7%
Institutional Inflows and Outflows
机构资金流入和流出
A number of large investors have recently modified their holdings of SLN. Frazier Life Sciences Management L.P. acquired a new stake in shares of Silence Therapeutics in the 1st quarter worth about $16,742,000. Lombard Odier Asset Management Europe Ltd acquired a new stake in shares of Silence Therapeutics in the 1st quarter worth about $29,669,000. Goldman Sachs Group Inc. increased its holdings in shares of Silence Therapeutics by 27.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company's stock worth $18,350,000 after acquiring an additional 205,815 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Silence Therapeutics in the 2nd quarter worth about $136,000. Finally, UBS Oconnor LLC increased its holdings in shares of Silence Therapeutics by 176.4% in the 3rd quarter. UBS Oconnor LLC now owns 79,636 shares of the company's stock worth $786,000 after acquiring an additional 50,820 shares during the period. 72.14% of the stock is currently owned by institutional investors.
一些大型投资者最近调整了对SLN的持股。Frazier生命科学管理公司在第一季度收购了Silence Treeutics的新股份，价值约16,742,000美元。隆巴德·奥迪尔资产管理欧洲有限公司在第一季度收购了Silence Treeutics价值约29,669,000美元的新股份。高盛股份有限公司在第一季度增持了寂静治疗公司的股份27.1%。高盛股份有限公司在此期间增持了205,815股，目前持有该公司965,815股股票，价值18,350,000美元。Citadel Advisors LLC在第二季度收购了Silence Treeutics的新股份，价值约13.6万美元。最后，UBS Oconnor LLC在第三季度增持了176.4%的Silence Treateutics股票。瑞银Oconnor LLC目前持有79,636股该公司股票，价值78.6万美元，在此期间又收购了50,820股。72.14%的股票目前由机构投资者持有。
Silence Therapeutics Company Profile
沉默治疗公司简介
(Get Rating)
(获取评级)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Silent Treateutics公司是一家生物技术公司，专注于血液学、心血管和其他罕见和代谢适应症的新型核糖核酸(RNA)疗法的发现和开发。该公司的平台包括mRNAi GalNAc寡核苷酸发现平台，旨在准确靶向肝脏中特定的疾病相关基因。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- 免费获取StockNews.com关于沉默治疗的研究报告(SLN)
- 为什么你应该避免Carvana，即使它可以避免破产
- 投资者是否听到了Spotify下跌趋势的终结？
- 美联储轴心的问题不是是否，而是何时，这是为什么
- 在MarketBeat All-Access上搜索的前10名股票
- 王室利好的3个股息之王
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《沉默治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Silence Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。